MedUni Vienna has made a crucial development in the treatment of Multiple Sclerosis (MS): Together with his team and the research group led by Gernot Schabbauer, international partners from Australia, Germany and Sweden, Christian Gruber, Chief Researcher at the Center for Physiology and Pharmacology has demonstrated in an animal model that, following treatment with a […]
Successful IPO with MedUni Vienna patent
Swedish company Cyxone, a subsidiary of ACCEQUA AB, headquartered in Malmö, recently went public – on the basis of a MedUni Vienna patent application relating to the potential development of an oral medication to combat multiple sclerosis. The invention “Cyclotides as immunosuppressive agents ” is the work of Christian Gruber from the Center for Physiology […]
Multiple sclerosis: Plant peptide could prevent onset of the disease
https://www.sciencedaily.com/releases/2016/03/160329101244.htm
Oral activity of a nature-derived cyclic peptide for the treatment of multiple sclerosis
http://www.pnas.org/content/113/15/3960.full
Oral activity of a nature-derived cyclic peptide for the treatment of multiple sclerosis
http://www.pnas.org/content/early/2016/03/22/1519960113.full.pdf http://tvthek.orf.at/program/ZIB-1/1203/ZIB-1/12317916/Hoffnung-fuer-Multiple-Sklerose-Patienten/12318077